- Home
- GBIO vs BOWN Comparison
GBIO vs BOWN Comparison
Compare GBIO & BOWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- BOWN
- Stock Information
- Founded
- GBIO 2016
- BOWN 2023
- Country
- GBIO United States
- BOWN United States
- Employees
- GBIO N/A
- BOWN N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- BOWN
- Sector
- GBIO Health Care
- BOWN
- Exchange
- GBIO Nasdaq
- BOWN Nasdaq
- Market Cap
- GBIO 29.2M
- BOWN 28.5M
- IPO Year
- GBIO 2020
- BOWN 2023
- Fundamental
- Price
- GBIO $0.41
- BOWN $9.20
- Analyst Decision
- GBIO Strong Buy
- BOWN
- Analyst Count
- GBIO 4
- BOWN 0
- Target Price
- GBIO $7.33
- BOWN N/A
- AVG Volume (30 Days)
- GBIO 1.2M
- BOWN 2.5K
- Earning Date
- GBIO 08-06-2025
- BOWN 01-01-0001
- Dividend Yield
- GBIO N/A
- BOWN N/A
- EPS Growth
- GBIO N/A
- BOWN N/A
- EPS
- GBIO N/A
- BOWN 0.02
- Revenue
- GBIO $24,556,000.00
- BOWN N/A
- Revenue This Year
- GBIO N/A
- BOWN N/A
- Revenue Next Year
- GBIO N/A
- BOWN N/A
- P/E Ratio
- GBIO N/A
- BOWN $206.51
- Revenue Growth
- GBIO 146.47
- BOWN N/A
- 52 Week Low
- GBIO $0.30
- BOWN $2.71
- 52 Week High
- GBIO $3.65
- BOWN $19.77
- Technical
- Relative Strength Index (RSI)
- GBIO 64.92
- BOWN 43.24
- Support Level
- GBIO $0.32
- BOWN $9.14
- Resistance Level
- GBIO $0.36
- BOWN $10.20
- Average True Range (ATR)
- GBIO 0.03
- BOWN 0.39
- MACD
- GBIO 0.01
- BOWN -0.03
- Stochastic Oscillator
- GBIO 93.81
- BOWN 39.35
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About BOWN Bowen Acquisition Corp
Bowen Acquisition Corp is a blank check company.